Stakeholders: ADAPT alone insufficient

Stakeholders at Friday's meeting of the House Energy and Commerce Committee's Subcommittee on Health agreed that the proposed Antibiotic Development To Advance Patient Treatment (ADAPT) Act is necessary but insufficient to fully address antibiotic resistance.

The subcommittee called upon FDA, industry, non-government agencies and academia to discuss ADAPT, as part of a larger hearing on antibiotic resistance and new drug development. ADAPT was introduced last December and would create an accelerated approval pathway for limited patient populations based on alternative endpoints. ...